--- title: "Diagnostic accuracy of GH stimulation tests after hypothalamic–pituitary radiotherapy: systematic" id: "bmj-open-9-diagnostic-accuracy-of-growth-hormone-stimulation-tests-for-growth-hormone" canonical_url: "https://medichelpline.com/clinical-feed/bmj-open-9-diagnostic-accuracy-of-growth-hormone-stimulation-tests-for-growth-hormone" content_type: "clinical_feed_article" specialty: "Endocrinology" source_name: "BMJ Open" source_url: "http://bmjopen.bmj.com/cgi/content/short/16/9/e125247?rss=1" published_at: "2026-09-21T12:57:18.000Z" evidence_level: "Journal Feed" license: "CC-BY-NC-4.0 / Informational Use" --- # Diagnostic accuracy of GH stimulation tests after hypothalamic–pituitary radiotherapy: systematic ## Provenance & Clinical Metadata - **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-open-9-diagnostic-accuracy-of-growth-hormone-stimulation-tests-for-growth-hormone - **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md) - **Primary Source:** BMJ Open - **Source URL:** [Original Journal Publication](http://bmjopen.bmj.com/cgi/content/short/16/9/e125247?rss=1) - **Published At:** 2026-09-21T12:57:18.000Z - **Evidence Rating:** Journal Feed ## Executive GIST (TL;DR) - Radiotherapy for intracranial, head and neck, and haematological malignancies often exposes the **hypothalamic‑pituitary (HP) axis** and can produce late endocrine effects, notably **growth hormone deficiency (GHD)**. - Clinical detection of GHD after HP‑axis radiotherapy is challenging because much of the evidence for **GH stimulation tests** comes from patient groups with different disease mechanisms than radiotherapy survivors. - This protocol outlines a systematic review, with planned meta‑analysis where feasible, to evaluate the diagnostic accuracy of GH stimulation tests for GHD across children, teenagers, young adults and adults who received radiotherapy involving the HP axis. - Eligible studies must include patients with prior HP‑axis radiotherapy who underwent GH stimulation testing for suspected GHD; index tests include insulin tolerance test, glucagon, arginine, clonidine, GHRH‑arginine and macimorelin tests. - Reference standards will consist of clinical criteria (≥2 additional pituitary hormone deficiencies) or alternative GH stimulation tests used as comparators. - Literature searches will be performed in MEDLINE, Embase, Cochrane Library and PubMed; two independent reviewers will perform screening and data extraction. - Risk of bias will be assessed with QUADAS‑2 and reporting quality with STARD criteria; sensitivity and specificity will be extracted and pooled using hierarchical bivariate and summary ROC models when studies are comparable. - Prespecified subgroup analyses will examine heterogeneity by age group, body mass index, ethnicity, radiotherapy dose and time since treatment. - No ethical approval is required because only published data are summarized; results will be disseminated via peer‑reviewed publications, conferences and clinical engagement. - The review is registered on PROSPERO (CRD420261415689). ## Clinical Analysis & Structured Key Points Introduction Radiotherapy is part of the treatment for many intracranial tumours, head and neck cancers and haematological malignancies. In these cases, the hypothalamic-pituitary (HP) axis is often included within the radiation field and can be damaged as an organ at risk. As survival improves, an increasing number of patients are living with late endocrine complications, particularly growth hormone deficiency (GHD). Diagnosing GHD in this context is challenging, as much of the evidence supporting growth hormone (GH) stimulation tests comes from populations with fundamentally different disease mechanisms. We aim to conduct a systematic review, and meta-analysis where feasible, to assess the diagnostic accuracy of GH stimulation tests for diagnosing GHD in children, teenagers, young adults and adults who have received radiotherapy involving the HP axis. Methods and analysis Eligible studies will include patients exposed to radiotherapy involving the HP axis, who subsequently underwent GH stimulation testing for suspected GHD. Index tests will include commonly used stimulation tests such as the insulin tolerance test, glucagon stimulation test, arginine stimulation test, clonidine stimulation test, GH-releasing hormone-arginine stimulation test and macimorelin stimulation test. Reference standards will include clinical criteria (≥2 additional pituitary hormone deficiencies) or alternative GH stimulation tests. Searches will be conducted in MEDLINE, Embase, Cochrane Library and PubMed. Two independent reviewers will screen studies, collect data, evaluate risk of bias using Quality Assessment of Diagnostic Accuracy Studies-2 and assess reporting quality using the Standards for Reporting of Diagnostic Accuracy Studies criteria. Sensitivity and specificity will be extracted. Where studies are sufficiently comparable, results will be pooled using hierarchical bivariate and summary receiver operating characteristic models. Prespecified subgroup analyses will explore heterogeneity by age group, body mass index, ethnicity, radiotherapy dose and time since treatment. Ethics and dissemination Ethical approval is not required as this systematic review summarises published data only. We will share our findings through peer-reviewed publications, conference presentations and engagement with relevant clinical teams to improve diagnostic decision-making in our population of interest. PROSPERO registration number CRD420261415689. ## Related Clinical Research - [Scalable encapsulation of pluripotent stem cell-derived islets in high-concentration alginate bead](https://medichelpline.com/clinical-feed/biorxiv-13-bridging-scale-up-to-transplantation-pluripotent-stem-cell-derived-pancreatic.md) - [INSR–BECN1–KIAA0825 complex prevents hepatocytic insulin receptor secretion and guards against mon](https://medichelpline.com/clinical-feed/biorxiv-17-an-insr-becn1-kiaa0825-complex-prevents-hepatocytic-insulin-receptor-secretion.md) - [Premature adrenarche and long-term metabolic risk: association with insulin resistance and hyperan](https://medichelpline.com/clinical-feed/pubmed-42375004.md) (DOI: 10.1210/clinem/dgag258) - [INSULIN Act Advances: Senate HELP Committee Passes Bill to Expand $35 Insulin Cap](https://medichelpline.com/clinical-feed/endocrine-news-0-endocrine-society-advocacy-win-senate-help-committee-passes-insulin-act.md) - [Optimised carbohydrate diet with increased resistant starch to improve metabolic health in adults](https://medichelpline.com/clinical-feed/bmj-open-14-optimised-carbohydrate-dietary-intervention-for-improving-metabolic-health-in.md) ## Navigation - [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md) - [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md) ## Medical & Regulatory Disclaimer > [!CAUTION] > MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations. > Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.